PFA
GSK icon

Pathway Financial Advisors’s GSK GSK Stock Holding History

Pathway Financial Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-819
Closed -$41K – 203
2018
Q2 		$41K Hold
819
– – 0.02% 281
2018
Q1 		$40K Hold
819
– – 0.02% 293
2017
Q4 		$36K Buy
+819
New +$37.8K 0.02% 310

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pathway Financial Advisors's GSK Position: Q3 2018 in Review

Pathway Financial Advisors sold out of GSK (GSK) in Q3 2018, closing a stake of 819 shares — an estimated $41K sold.

Pathway Financial Advisors first reported a position in GSK in Q4 2017 and held it in 3 quarters. The position peaked at $41K in Q2 2018. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

  • Pathway Financial Advisors reported no remaining GSK position as of Q3 2018 after selling out during the quarter.
  • Pathway Financial Advisors sold 819 GSK shares in Q3 2018, an estimated $41K.
  • Pathway Financial Advisors first reported a position in GSK in Q4 2017 and held it in 3 quarters.
  • Pathway Financial Advisors's GSK position peaked at $41K in Q2 2018.
  • 787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Pathway Financial Advisors's 13F filing for Q3 2018, filed 16 Jan 2019.